|
|
 |
|
Viewing report
|
|
|
|
U.S. Breast Cancer Therapeutics Markets
Frost & Sullivan, March 2008, Pages: 78
This report analyzes the U.S. breast cancer therapeutics market, for the forecast period 2000 to 2010. The report is segmented into 5 chapters viz. Executive Summary, Total Market, Cytotoxic Therapeutics Market, Hormonal Therapeutics Market, and Biologic Therapeutics Market. Each segment provides revenue forecasts, market share, pricing trends, demand analysis, competitive structure and market and product trends. Drivers, restraints and challenges and the strategic recommendations are also discussed. Frost & Sullivan Awards are conferred on deserving companies.
Robust Pipeline to Drive Growth of Breast Cancer Therapeutic Industry
With increasing public awareness about breast cancer and its treatment, the market for breast cancer therapeutics is primed for expansion. However, impending patent expirations and the resulting competition from generic drugs is expected to hamper growth, especially in the cytotoxic and hormonal segments. These sectors also face a threat from emerging therapies that promise to improve the quality of the patient's life. Drugs maintaining strong proprietary patent positions, such as Herceptin, a monoclonal antibody, are likely to be relatively secure over the forecast period, 2000-2010, while many aromatase inhibitors and selective estrogen receptor modulators (SERM) are anticipated to lose proprietary patent holdings. In order to counter the effects of this loss, large pharmaceutical companies need to fill their pipelines with newly patented therapies and transition patients onto the next generation therapies.
This research service analyzes the cytotoxic, hormonal, and biologic sectors of the U.S. breast cancer therapeutics market. It discusses many different competitive factors within the breast cancer therapeutics market including revenue forecasts, product differentiation, clinical trials, and pipeline therapies.
New Treatment Strategies for Adjuvant Therapy Stimulate Market Growth
'A robust pipeline of biologics, hormonals, chemopotentiators and chemoprotectants can drive the growth of the breast cancer therapeutic industry by introducing innovative adjuvant therapies to combat early stage disease,' says the analyst. Since cancer cells tend to metastasize even if the cancer has not spread, systemic control of the disease using adjuvant therapy - hormonal, cytotoxic, or biologic - is required to improve the long-term outlook for patients. The wider use of more effective and expensive adjuvant therapies is likely to boost sales.
Growth in the hormonal segment depends on the ability of pharmaceutical companies to convince oncologists and patients about the proven clinical benefits of their newer and more expensive therapies. Companies that can demonstrate their drug's efficacy and safety can expect to be rewarded in this large and growing market.
Intense Competition among Major Pharmaceuticals Targets Expanding Customer Base
With adjuvant and extended adjuvant label therapies gaining popularity, major pharmaceutical companies are engaged in intense clinical trials in a bid to capture the expanding patient base. Researchers are coming up with new and more effective combinations of chemotherapy and hormonal drugs. To date, tamoxifen has been the gold standard in hormonal anti-estrogen therapy to fight breast cancer. Many innovative therapies are now being tested for their efficacy against this standard.
As more targeted biologic therapies reach the market after extensive clinical tests, patients will have more options to prevent further recurrence of the disease. 'With numerous drugs filling the SERM and aromatase inhibitor segments, oncologists and patients are driving the demand for the most effective preventive treatment for hormone receptor-positive breast cancer,' concludes the analyst.
Customers who bought this item also bought
Breast Cancer - Therapeutic And Competitive Insights
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
Breast Cancer Drug Discoveries: What the Future Holds
Stakeholder Insight: Hormonal Therapies in Breast Cancer
Breast Cancer Therapeutics - Global Strategic Business Report
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Cancer Therapies - Global Strategic Business Report
Cancer Therapies - Global Market Opportunities
Cancer Therapies - Global Market Opportunities
Drugs of Tommorow 2002: Breast Cancer
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
|
|
|
|
